ATE419834T1 - Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren - Google Patents

Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Info

Publication number
ATE419834T1
ATE419834T1 AT01274072T AT01274072T ATE419834T1 AT E419834 T1 ATE419834 T1 AT E419834T1 AT 01274072 T AT01274072 T AT 01274072T AT 01274072 T AT01274072 T AT 01274072T AT E419834 T1 ATE419834 T1 AT E419834T1
Authority
AT
Austria
Prior art keywords
drug
copolymers
vinyl
vinyl acetate
surface stabilizers
Prior art date
Application number
AT01274072T
Other languages
English (en)
Inventor
Henry Bosch
Niels Ryde
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE419834T1 publication Critical patent/ATE419834T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01274072T 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren ATE419834T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
ATE419834T1 true ATE419834T1 (de) 2009-01-15

Family

ID=24872726

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274072T ATE419834T1 (de) 2000-11-20 2001-11-16 Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren

Country Status (8)

Country Link
EP (1) EP1341521B1 (de)
JP (2) JP4541647B2 (de)
AT (1) ATE419834T1 (de)
AU (1) AU2001297844A1 (de)
CA (1) CA2428785C (de)
DE (1) DE60137362D1 (de)
ES (1) ES2317874T3 (de)
WO (1) WO2002094215A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2593862C (en) * 2004-12-31 2014-10-21 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
EA200702595A1 (ru) * 2005-05-23 2008-12-30 Элан Фарма Интернэшнл Лимитед Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов
US8877217B2 (en) * 2005-10-18 2014-11-04 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
WO2008000042A1 (en) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
SG10201401695VA (en) 2009-04-24 2014-08-28 Iceutica Pty Ltd A novel formulation of indomethacin
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
WO2013125232A1 (ja) * 2012-02-23 2013-08-29 キヤノン株式会社 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
JP2018507209A (ja) 2015-02-20 2018-03-15 サイテック インダストリーズ インコーポレイテッド ジアルキルスルホスクシナート組成物、製造方法、および使用方法
US20200093956A1 (en) * 2016-03-24 2020-03-26 Locate Therapeutics Limited Scaffolding material, methods and uses
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
DK3928772T3 (da) 2020-06-26 2024-08-19 Algiax Pharmaceuticals Gmbh Nanopartikulær sammensætning

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
EP1293504A3 (de) * 1996-07-08 2003-11-05 Ciba SC Holding AG Triazinderivate als UV-Filter in kosmetischen Mitteln
IL128632A (en) * 1996-08-22 2003-03-12 Rtp Pharma Corp Compositions comprising microparticles of water-insoluble substances and method for preparing same
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Also Published As

Publication number Publication date
JP2010111685A (ja) 2010-05-20
ES2317874T3 (es) 2009-05-01
CA2428785A1 (en) 2002-11-28
EP1341521A2 (de) 2003-09-10
CA2428785C (en) 2011-04-26
AU2001297844A1 (en) 2002-12-03
WO2002094215A2 (en) 2002-11-28
DE60137362D1 (de) 2009-02-26
JP2004520443A (ja) 2004-07-08
WO2002094215A3 (en) 2003-05-01
EP1341521B1 (de) 2009-01-07
JP4541647B2 (ja) 2010-09-08

Similar Documents

Publication Publication Date Title
ATE419834T1 (de) Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
DE60332212D1 (de) Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
EA200701274A1 (ru) Нанодисперсные составы на основе такролимуса
DE602004021107D1 (de) Meloxican-formulierungen in nanoteilchenform
EA200601468A1 (ru) Частицы
ES2191616T3 (es) Polvos pulverizables de fluoropolimeros no fibrilables.
DK1429731T3 (da) Nanopartikelformuleringer indeholdende insulin
WO2005044234A3 (en) Nanoparticulate compositions having a peptide as a surface stabilizer
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
DE602005027477D1 (de) Arzneimittelabgabe aus embolischen mitteln
HRP20100372T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba
DE602005025083D1 (de)
HRP20070198A2 (en) Compositions of estrogen-cyclodextrin complexes
WO2005049091A3 (en) Antibody-targeted nanoparticulate active agent delivery
HUP0402280A2 (hu) Mikronizált filmképző por, az ezt tartalmazó készítmények, eljárások ezek előállítására, és ezek alkalmazása
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
DE602004019546D1 (de) Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
ATE459345T1 (de) Wirkstoffpartikelhaltiges transdermales therapeutisches system mit erhöhtem wirkstofffluss
UA94917C2 (ru) Композиции для местного применения
BR0209020A (pt) Composição farmacêutica de polialilamina
ATE376978T1 (de) Nanopartikel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties